Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Memphasys has added another piece to the commercialisation puzzle for its Felix sperm-selection technology, signing a three-year Nordic distribution agreement carrying minimum contracted purchases of €526,500.

The deal appoints Denmark-based NOVIVITAE as the exclusive commercialisation partner for Denmark, Sweden, Norway, Finland and Iceland, taking Memphasys' European commercial footprint to nine countries alongside Italy, the United Kingdom, Türkiye and Poland.

For investors, the significance lies less in the headline geography and more in the structure of the agreement. The Nordic arrangement includes minimum purchases, quarterly ordering requirements and performance obligations, giving Memphasys greater visibility over prospective revenue than a looser distribution relationship might provide.

There is also an immediate order worth €20,625 to be supplied and invoiced in the September quarter, providing a modest near-term contribution while the partners undertake a three-month evaluation and market-development period.

Contracted revenue starts to build

The €526,500 minimum contracted value spans three agreement years following the initial evaluation period, equivalent to an average of €175,500 a year if spread evenly.

That figure is not transformative by itself, but it is another indication that Memphasys is progressing from product development into a more measurable commercial phase.

Importantly, the agreement is structured around increasing minimum purchase commitments. That means the commercial test will not simply be whether Felix can enter Nordic clinics, but whether initial adoption can translate into repeat cartridge consumption and progressively larger orders.

Felix uses a disposable cartridge for each procedure, so the longer-term revenue opportunity depends heavily on utilisation after systems are installed. Hardware placement opens the door, but recurring consumables are potentially where commercial scale becomes more meaningful.

The company says the Nordic region recorded about 55,000 assisted reproductive technology treatment cycles in 2020 across the five target countries. It also stresses that the figure is a historical benchmark affected by COVID-19 rather than a current market forecast.

Distributor quality will matter as much as territory size

NOVIVITAE supplies IVF and laboratory technology to clinics and sperm and egg banks across the Nordic region. Its role will extend beyond product distribution to clinic engagement, demonstrations, training, relationships with fertility specialists and embryologists, and first-line customer support.

That boots-on-the-ground approach is important for a product such as Felix, where commercial adoption is likely to involve changes to established laboratory processes.

Rather than selling a conventional consumable into an existing workflow, Memphasys is asking clinics to adopt an alternative sperm-selection method. Felix combines electrophoresis and size-exclusion membranes and is designed to replace traditional centrifugation with a faster, standardised process intended to reduce cellular stress and DNA damage.

NOVIVITAE managing director Søren Venderby said the distributor was already seeing "strong early interest" from IVF clinics, particularly around the technology's clinical benefits and potential improvements to laboratory workflow and efficiency.

Early interest is encouraging, but investors will want to see that interest converted into orders once demonstrations and evaluations move into routine clinical use.

Europe is becoming the main commercial proving ground

The Nordic expansion also reinforces the emerging European focus of the Felix roll-out.

Memphasys now has commercial sales or agreements spanning nine European countries, giving it a broader distributor network through which it can test demand, build reference clinics and develop recurring cartridge sales.

Non-executive director and commercialisation committee chair Marjan Mikel described the agreement as another step in expanding Felix's European footprint and pointed to further advanced commercial discussions across the region.

The company is also strengthening its internal commercial resources, with its Director of Commercial Operations-Europe due to commence in mid-September.

That combination of local distributors and dedicated European commercial leadership suggests Memphasys is moving toward a more coordinated regional strategy rather than relying on isolated country-by-country deals.

Execution now becomes the key investor metric

The next three months will centre on distributor training, market-development planning, clinic engagement and product demonstrations, alongside delivery of the initial order.

After the evaluation period, quarterly minimum purchase commitments begin.

That creates a relatively clear sequence of milestones for investors to watch. The first is fulfilment of the initial order. The second is whether NOVIVITAE progresses clinics from demonstrations to adoption. The third, and more important, is whether minimum purchase commitments are met and ultimately exceeded as cartridge usage grows.

The €526,500 contracted minimum gives the Nordic agreement more substance than a simple appointment of a distributor, but it remains small relative to what would eventually be required to establish Felix as a meaningful global commercial product.

The broader investment case therefore continues to rest on replication. One distribution agreement demonstrates access to a market. A network of distributors consistently meeting rising purchase commitments would demonstrate a scalable business model.

For Memphasys, the Nordic deal expands both its European reach and its pool of contracted future sales. The next challenge is turning that widening footprint into repeatable clinic utilisation and recurring consumables revenue.

The Agency Group Australia has closed FY26 with record Gross Commission Income, a larger agent network and a sizeable improvement in underlying earnings, but the second-half slowdown and an increasingly difficult residential property market leave investors with a more complicated picture heading into FY27.

Gross Commission Income, or GCI, rose 21% to a record $151.6 million, comfortably clearing the company's previous run-rate milestone of around $150 million. Revenue increased 10% to $108.7 million, while gross profit climbed 11% to $35.7 million and gross margin edged higher from 32.5% to 32.8%.

For investors, the standout earnings number was underlying EBITDA before AASB 16, which increased 59% to $1.79 million. Statutory EBITDA rose 29% to $4.86 million, while the statutory net loss narrowed sharply to $2.37 million from $5.44 million.

That is genuine progress, although profitability remains modest relative to the scale of the commissions flowing through the network.

More agents, higher property values

The operational engine was the sales network.

Agent numbers increased 16% to a record 511, compared with 442 a year earlier. Listings rose 5% to 7,971, while the number of properties sold increased 3% to 6,849.

The more telling number was gross sales value, which jumped 21% to $9.02 billion. Average sale price increased 18% to around $1.32 million, reflecting a greater contribution from higher-value markets.

Revenue per agent also rose 4% to approximately $62,400.

That combination matters. The Agency is not simply adding headcount, but appears to be extracting somewhat more revenue from each agent while broadening its geographic base. Growth in GCI was led by Queensland, Tasmania, New South Wales and Victoria, while Western Australia remained the largest contributor despite softer transaction volumes.

Executive Chairman Andrew Jensen said the result demonstrated "the value of our national platform and the operating leverage available as productive agents and established offices join the network".

The key word is productive. Recruiting agents is useful only if those additions ultimately contribute enough commission income to cover the central platform costs.

Second-half softness is the main wrinkle

The full-year numbers look considerably stronger than the exit rate.

The Agency generated underlying EBITDA of $2.06 million in the first half, meaning the second half produced an underlying EBITDA loss of around $270,000.

Management attributed that reversal to the normal seasonality of agent remuneration structures, investment in the larger network and cooling housing activity late in FY26.

That second-half performance deserves attention because the softer market has carried into FY27.

National sales volumes have weakened, selling periods have lengthened, advertised stock has risen and buyers have gained greater negotiating power. The company also highlighted falling dwelling values across major capital-city markets and the impact of higher borrowing costs.

In other words, FY26's record GCI was achieved largely before the market became appreciably tougher.

Property management provides a useful ballast

Property management continues to provide the recurring revenue component that helps offset the cyclicality of residential sales.

Property management revenue rose 7% to $14.48 million, with management fee revenue from the company-owned portfolio increasing to $10.54 million from $9.76 million.

The combined portfolio reached 12,261 properties, comprising 5,481 owned management rights and another 6,780 properties managed under service arrangements.

There is also an interesting balance-sheet wrinkle. The independently assessed value of the owned rent rolls was approximately $38.1 million, yet only $2.68 million was recognised on the balance sheet. Management therefore estimates that about $35.42 million of rent roll value is not reflected in reported net assets.

Investors should distinguish carefully between assessed asset value and readily available cash, however. Cash stood at $4.24 million at year end, down from $5.07 million, while reported net assets fell to just $80,000.

That leaves little accounting balance-sheet cushion despite the claimed underlying value of the property management portfolio.

A big pipeline, but not yet revenue

The July listing pipeline increased to 2,813 properties from 1,878 a year earlier.

Based on current listing values and historical commission rates, management estimates those listings could represent around $75 million of potential GCI, or $69.4 million after applying a 7.5% prudence adjustment.

Importantly, this is not guidance. Listings can be withdrawn, delayed, repriced or fail to convert.

Still, the 58% increase in indicative pipeline GCI provides some evidence that the larger agent network is feeding more potential transactions into the system.

Aura proposal adds another moving part

Investors also have a possible corporate transaction to consider.

Aura Group has put forward a confidential, non-binding and conditional scrip-for-scrip merger proposal based on an indicative transaction price of 4 cents per The Agency share, with Aura's valuation still under discussion and the proposal conditional on Aura listing on the Australian Securities Exchange.

Exclusivity has been granted for due diligence and documentation, but there is no binding agreement and no certainty a transaction will proceed.

Until those conditions change, the operational business remains the more useful lens.

FY27 becomes the credibility test

The Agency has surpassed its $150 million GCI ambition and retains longer-term targets of $175 million and eventually $200 million, although management is not providing FY27 earnings or GCI guidance.

The central investor question is therefore whether the enlarged national network can continue converting scale into earnings while residential conditions weaken.

FY26 showed meaningful improvement: record GCI, more agents, rising productivity, growing recurring revenue and a sharply reduced statutory loss. The counterweight is a weak second-half earnings finish, a thin reported net asset position and a property market that entered FY27 with considerably less momentum.

The Agency has become bigger. FY27 will show whether it has also become materially more resilient.

Memphasys has taken another important step in turning its Felix sperm separation technology from a development story into a commercial one, securing Thai Food and Drug Administration approval earlier than expected and clearing the final regulatory hurdle for sales in Thailand.

The approval activates the company's exclusive three-year distribution agreement with IVF Envimed Co., Ltd., carrying minimum contracted purchases of approximately $430,500. More importantly, the distributor has already responded to early interest from fertility clinics by placing an additional order for 100 Felix cartridges and three paid consoles. That follows an initial order for 100 cartridges and three consoles when the distribution agreement was signed.

For investors, the significance is not merely another regulatory tick. Thailand can now move from business development and clinic discussions to product delivery, training, onboarding and commercial use.

That distinction matters for a company still operating from a modest revenue base. Recent market data values Memphasys at roughly $18.5 million, while trailing revenue remains only about $214,000. The commercial question is therefore increasingly straightforward: can regulatory approvals and distribution agreements convert into repeatable cartridge sales at sufficient scale?

The first orders offer an encouraging signal

The extra 100-cartridge order is modest in dollar terms, but strategically it is arguably more meaningful than the initial contractual commitment.

IVF Envimed has relationships with all 110 registered IVF clinics in Thailand, supported by a six-person field sales team, service engineers, logistics capability and clinical education programs. Rather than Memphasys having to build a sales force clinic by clinic, the company is effectively plugging Felix into an existing reproductive medicine distribution network.

Management says early clinic interest has been driven by Felix's potential clinical benefits, including reduced sperm DNA fragmentation and improved embryo utilisation, as well as a six-minute sperm preparation process.

Thailand is also a potentially useful market for a consumables-driven device. The country conducts an estimated 20,000 to 30,000 IVF cycles each year, with more than 95 per cent involving intracytoplasmic sperm injection. Each Felix procedure requires a disposable cartridge, meaning the long-term economics depend less on selling consoles and more on how frequently installed systems are actually used.

That is the key metric investors will eventually want to see.

Contracted revenue starts to climb

The Thai contract requires minimum purchases of $75,000 in year one, $143,000 in year two and $212,000 in year three.

Management believes year-one revenue could exceed the $75,000 minimum, depending on customer demand and timing. Commercialisation committee chair Marjan Mikel described the additional orders as "exactly the commercial validation we want to see" and said the company was confident of exceeding the first-year minimum.

The stepped purchasing commitments are worth watching. They assume 91 per cent growth in minimum purchases between years one and two, followed by another 49 per cent increase in year three. That structure means the distributor is expected to progressively deepen penetration rather than simply conduct an extended market trial.

There is still a substantial difference between contractual minimums and widespread clinical adoption, however. The investment case will increasingly depend on placements, utilisation rates and repeat cartridge orders rather than the headline number of clinics theoretically accessible.

South-East Asia is becoming a genuine commercial beachhead

Thailand follows the recent regulatory approval of Felix in Vietnam, where Memphasys has a separate two-year commercial agreement with TMSC Viet Nam Medical Technology Company Limited.

Together, the Thai and Vietnamese agreements represent approximately $1 million in minimum contracted value. That is becoming meaningful relative to Memphasys' historical revenue base, although the contracts extend over multiple years and actual revenue recognition will depend on product supply and customer purchasing.

The geographical pattern is also notable. Memphasys is assembling a distribution-led commercial network rather than carrying the cost of establishing wholly owned sales operations in every country. For a small biotechnology company, that can provide market reach with relatively limited fixed infrastructure, although it also leaves execution partly in the hands of local partners.

Now comes the harder part - utilisation

Regulatory approval removes one risk, but it exposes the next one.

Near-term work includes delivery of the first-quarter order, training IVF Envimed staff, onboarding clinics and commencing commercial use. Memphasys says it will update investors when clinic placements, cartridge utilisation and subsequent orders become material.

Those numbers should provide the clearest evidence of whether Felix is moving beyond distributor enthusiasm to routine clinical adoption.

The early Thai approval and repeat order are encouraging commercial signals. The next milestone is less glamorous but considerably more important: getting cartridges used, reordered and used again. For Memphasys, recurring consumable revenue is where the Felix story ultimately has to prove itself.

hummgroup has closed FY26 with a result that gives investors two quite different numbers to chew over.

Statutory profit after tax fell 60.4% to $15.7 million, but underlying net profit after tax adjusted for non-cash items and excluding irregular items came in at $44.2 million. The sizeable gap reflects $19.1 million of irregular items before tax, including costs associated with Forum Finance litigation, corporate activity, regulatory matters, remediation and restructuring.

The distinction matters because FY26 was anything but a quiet year. Management was juggling takeover approaches, board and shareholder ructions, regulatory investigations and litigation while trying to keep the lending machinery turning.

Chief executive Angelo Demasi said the year demonstrated "the resilience of hummgroup's operating model and the benefits of disciplined execution" despite macroeconomic pressure and an unusually heavy corporate workload.

Average assets under management were essentially flat at $5.2 billion, while closing AUM slipped 4.3% to $5.26 billion. Total volumes fell 10.5% to $3.50 billion, largely because of the planned wind-down of the legacy humm Classic product and softer commercial lending demand.

For investors, the key question is whether FY26 represents an earnings trough created by transition costs and legacy distractions, or whether slower lending growth is becoming more structural.

Margins improve, but credit losses edge higher

There was some encouragement on pricing.

Group net interest margin rose 10 basis points to 5.5%, helped by lower funding costs, disciplined pricing and a shift towards higher-yielding Consumer receivables. Consumer NIM climbed 50 basis points to 8.6%, while Commercial remained broadly stable at 3.4%.

That margin expansion provided an important cushion against weaker volumes.

Credit quality, however, bears watching. Group net credit losses increased to 2.0% of average net receivables from 1.8%. Commercial losses rose to 1.5% as earlier lending vintages seasoned and recovery periods lengthened in a softer SME environment.

The contrast within Consumer was more favourable. Australian Cards net losses improved to 2.3% from 2.7%, while Ireland and the UK also produced solid credit outcomes. New Zealand Cards edged higher to 3.5%, reflecting tougher economic conditions.

The message is reasonably clear: credit remains controlled, but investors should not assume the economic cycle has stopped knocking at the door.

Consumer emerges as the earnings engine

Consumer was the standout segment.

Net profit after tax adjusted for non-cash items increased 25.8% to $31.2 million, while statutory Consumer profit more than doubled to $26.9 million. Australian Cards statutory profit jumped 79.5% to $13.1 million, while New Zealand Cards increased 27.9% to $14.2 million.

Those gains came despite Consumer volumes falling 12.2% to $2.10 billion.

The explanation lies in mix, credit and costs. Consumer operating expenses fell 7.8%, credit losses improved 3.5% and higher-margin international businesses gained ground.

Ireland delivered 27.8% volume growth, while UK volumes increased 41.1%. Canada, meanwhile, completed a reset that cut operating expenses by $4.5 million, although volumes fell 18.3% as management tightened the merchant network and focused on higher-quality originations.

The Australian point-of-sale business remains the transition story. Legacy humm Classic volumes are running off while the regulated hummloan product scales up. Approved hummloan originations reached $306.7 million during FY26, with management expecting growth on the new platform to largely offset the legacy decline during FY27.

That inflection point could prove central to the Consumer division's next phase.

Commercial growth cools as losses rise

Commercial was more subdued.

Volumes fell 7.9% to $1.41 billion as SME lending demand weakened, particularly across diesel-dependent vehicles and machinery. Even so, average Commercial AUM rose 5.1% to $3.33 billion and June monthly volume exceeded $160 million.

Statutory Commercial profit dropped 46.8% to $23.2 million, while profit adjusted for non-cash items declined 24.9% to $34.0 million.

Management is emphasising stronger credit settings and pricing discipline rather than chasing volume. That may limit near-term growth, but after several years of portfolio expansion, investors will arguably care more about loss trends than another burst of originations.

Funding and dividends provide some ballast

The balance sheet enters FY27 with $5.4 billion of on-balance-sheet wholesale debt facilities and $1.4 billion of undrawn capacity, including Forward Flow capacity.

The board declared a final dividend of 0.50 cents per share, taking full-year dividends to 2.00 cents per share, fully franked. Management described that as a 4.5% annualised shareholder return.

The more important development may be that many of the distractions which dominated FY26 are now described as substantially resolved. That should free management to focus on platform transformation, automation, AI adoption, cost efficiency and capital allocation.

There is no numerical FY27 earnings guidance, so investors are being asked to judge the direction of travel rather than a promised destination.

If the transition in Australian consumer lending reaches the anticipated inflection point, international growth continues and Commercial credit losses stabilise, the earnings mix could improve materially. If not, FY26's underlying resilience may prove more defensive than transformational.

For now, hummgroup enters FY27 leaner, better funded and with fewer corporate fires to extinguish. The next test is whether all that housekeeping finally turns into cleaner profit growth.

Gold Hydrogen has added another important piece to the Ramsay puzzle, with flow testing at its second well confirming high-grade helium, strong reservoir productivity and, crucially, evidence that the helium-bearing Kulpara Dolomite extends beyond a single well.

For investors, the significance is less about simply finding helium again and more about repeatability. Ramsay 2 has flowed helium at air-corrected concentrations of up to 20%, closely matching the stabilised 19% concentration previously recorded at Ramsay 1. The two wells are around 500 metres apart, giving Gold Hydrogen its first dynamic evidence that the thick helium-bearing reservoir may be laterally continuous.

That pushes Ramsay another step along the journey from an intriguing geological discovery towards something that might ultimately support a commercial development.

High-grade helium appears repeatable

The headline number is the helium concentration.

Testing of the 180-metre gross Kulpara Dolomite interval at Ramsay 2 produced air-corrected helium concentrations of up to 20%, while the deeper Hiltaba Basement returned concentrations of up to 19%.

These are field measurements and remain subject to independent laboratory confirmation, an important qualification investors should keep firmly in mind. Even so, the consistency with Ramsay 1 is encouraging because it reduces the risk that the original result represented an isolated sweet spot.

Managing director Neil McDonald said the company had progressed from demonstrating high-grade helium production and purification at Ramsay 1 to showing "repeatable high-grade Helium extraction" at Ramsay 2.

The other notable feature is the thickness of the target. Gold Hydrogen describes the Kulpara interval as a 180-metre gross helium-bearing reservoir and says it is unaware, based on published information, of another helium-only bearing zone globally with comparable thickness.

That claim is ambitious, but the more investable question is whether the reservoir can deliver enough fluid and helium consistently enough to underpin commercial economics.

Reservoir productivity could prove just as important as grade

Ramsay 2 produced gross fluid rates of up to 2,300 barrels per day, with stabilised rates of about 1,200 barrels per day while the electrical submersible pump was operating at its rated capacity.

The company says testing was constrained by equipment and completion design rather than reservoir deliverability. It estimates raw gas rates of up to about 128,000 standard cubic feet per day and helium rates of up to roughly 24,300 standard cubic feet per day from the Kulpara Dolomite.

Perhaps more interesting is the reported reservoir productivity index of up to approximately 34 barrels per day per psi. Gold Hydrogen contrasts this with productivity below two barrels per day per psi in many commercial low-permeability reservoirs.

That matters because Ramsay's helium is produced alongside formation water. The easier and more efficiently that water can be lifted, the greater the potential gas recovery.

The cased-and-perforated completion at Ramsay 2 improved pump efficiency by almost three times compared with Ramsay 1. That provides useful operating data ahead of Ramsay 3, where the company intends to progressively test pumping rates towards 20,000 barrels per day.

Ramsay 3 now becomes the next major test

Ramsay 3 will be watched closely because it should help determine whether Gold Hydrogen can scale the system beyond the relatively modest pump capacities used so far.

The company has previously cited an independent Worley assessment suggesting a commercial helium development could potentially operate with as few as two wells, subject to further technical, economic and commercial work.

Ramsay 2 strengthens the technical side of that argument, but it does not settle it.

No long-term commercial flow rate has yet been demonstrated, project economics remain unproven and the company has not yet booked Contingent Resources. The current helium resource remains classified as Prospective Resources, with a mean estimate of 96 billion cubic feet across the assessed project area. The estimate is unrisked and relates to quantities that may potentially be recovered from undiscovered accumulations.

Gold Hydrogen expects to assess maiden Contingent Resources after completing and interpreting the full 2026 flow-testing program, including Ramsay 3.

From geology towards development planning

Meanwhile, Gold Hydrogen is already looking beyond appraisal.

Planning is continuing for a potential helium pilot project, with preliminary discussions under way with technology and distribution partners. The company is also considering an accelerated front-end engineering design program and assessing modular commercial helium plant options.

That creates a fairly clear sequence for investors to follow: complete Ramsay 3, establish whether the reservoir performance can be replicated at higher pumping rates, progress towards Contingent Resources and then tighten the engineering and economics around a pilot development.

The deeper Hiltaba Basement adds another wrinkle. Its 19% air-corrected helium reading suggests Ramsay may contain more than one productive helium-bearing interval, although much more appraisal work will be required before that potential can be quantified confidently.

For now, Ramsay 2 has achieved something more valuable than another eye-catching helium grade. It has demonstrated that helium production, reservoir characteristics and strong deliverability can be repeated at a second location.

That does not make Ramsay commercial. But it does make the project considerably harder to dismiss as a one-well curiosity.